Status:
COMPLETED
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
Lead Sponsor:
LL Prosper Inc.
Conditions:
Aging
Inflammation
Eligibility:
All Genders
50-75 years
Phase:
NA
Brief Summary
This is a prospective, interventional, double-blinded placebo-controlled study of up to 40 participants to evaluate the effect of a botanical formulation on inflammatory biomarkers and epigenetic age.
Detailed Description
The objective of this study is to understand the impact of a multi-botanical formulation on measurements of protein markers, with a focus on inflammation over a 60-day period. The primary objective of...
Eligibility Criteria
Inclusion
- Age: 50-75 years of age
- Any sex / gender
- All ethnicities
- Able to participate in a 2 month trial
- Able to provide informed consent
- Participant must be able to comply with treatment plan and laboratory tests
- Can swallow 00 size capsules
Exclusion
- Any clinically diagnosed medical disease or disorder that requires prescribed medication(s)
- Currently on any anticoagulant medicines, such as warfarin
- Planned surgical procedure during study period
- Consumption of any supplements within the last 30 days that include the following botanicals/ingredients: green tea extract, Ashwagandha, Fisetin, Curcumin/Turmeric extract, Rosemary extract, Cordyceps, Ginseng
- Allergy or other sensitivity to any of the botanicals in the investigated product
- Currently or have been sick (bacterial or viral infection) in the last 14 days
- Alcoholism or drug addiction
- Participation in a clinical research trial within 30 days prior to enrollment in this trial
- Cognitive impairment, illiteracy, inability or unwillingness to give voluntary informed consent
- Unable or unwilling to provide required blood sample for testing and for use in a scientific publication (personal information undisclosed)
- Participants with any condition that may preclude venipuncture/ venous blood draw
Key Trial Info
Start Date :
September 22 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2024
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06065241
Start Date
September 22 2023
End Date
March 28 2024
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LL Prosper Inc.
San Diego, California, United States, 92121